Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy.

Abstract

Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhibitors combination therapy is limited. In this report, a case of tubulointerstitial nephritis that developed in a rheumatoid arthritis patient with advanced melanoma treated with encorafenib plus dabrafenib combination therapy is presented.

• Authors: Yumi Kambayashi, Kentaro Ohuchi, Hiromu Chiba, Erika Tamabuchi, Tasuku Nagasawa, Yoshihide Asano, Taku Fujimura
• Journal: Case reports in oncology (Case Rep Oncol) 2022 May-Aug Vol. 15 Issue 2 Pg. 469-472 ISSN: 1662-6575 [Print] Switzerland
• PMID: 35702675 (Publication Type: Case Reports)
• Copyright: Copyright © 2022 by S. Karger AG, Basel.